Semax
Also known as: ACTH(4-10) analog, Met-Glu-His-Phe-Pro-Gly-Pro
What Is Semax?
Semax is a synthetic heptapeptide — an analog of the ACTH(4-10) fragment extended at the C-terminus with a Pro-Gly-Pro (PGP) tail that resists enzymatic breakdown and gives the molecule far greater stability than the native ACTH fragment. It was developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences.
In Russia, Semax is a registered pharmaceutical, sold as intranasal formulations for cognitive and cerebrovascular indications (a lower-strength preparation for asthenia, memory, and attention; a higher-strength one for acute ischemic stroke). It has never been through Western clinical development and is not FDA-approved for any indication. On the grey market it’s marketed as a nootropic — for focus, memory, and neuroprotection.
What the Evidence Actually Shows
This is where the marketing and the literature diverge. Most of the published Semax research is animal (rat) and in-vitro work, much of it from the originating Russian group, focused on cerebral-ischemia gene and protein expression and on neurotrophin (BDNF/NGF) pathways. The mechanistic story — that Semax upregulates neurotrophins and modulates monoamine systems — is reasonably supported in rodents.
The human evidence is real but thin, and almost entirely Russian. The best-indexed human trial (Gusev 2018) is a small, single-country study in ischemic-stroke patients; it reported raised BDNF and improved functional recovery, but the published abstract does not report effect sizes or statistical detail, which limits how much weight it can bear. There are no verifiable rigorous Western or multicenter randomized controlled trials. Claims circulating on vendor sites about placebo-controlled crossover studies in healthy adults could not be tied to any real citation and are excluded here.
That combination — genuine (if limited) human clinical use plus a large animal literature, but no Western RCTs — is why we rate Semax limited-human rather than “moderate-human.”
Legal and Regulatory Status
FDA: Removed from Category 2 on April 15, 2026. Removal from the “do not compound” list is not authorization — Semax is not yet on the 503A compoundable list, so licensed pharmacies still cannot lawfully compound it. PCAC reviews Semax on July 24, 2026; any move onto the compoundable list would still require subsequent FDA rulemaking. Not FDA-approved for any indication.
WADA: Not explicitly named on the Prohibited List. As a non-approved pharmacological substance, it is plausibly captured under S0 (non-approved substances), which prohibits it in sport at all times — but WADA has not classified it by name.
Ahead of the July 2026 PCAC meeting, secondary reporting indicated the FDA flagged Semax for a possible bleeding-risk signal, potentiation of amphetamine-induced dopamine release in animals, and a 2025 adverse-event report involving an intranasal Semax product bought online. We have not independently confirmed these details against the primary FDA briefing document and present them as reported concerns, not established fact.
Common Vendor Claims vs. Reality
| What vendors say | What the evidence shows |
|---|---|
| ”Clinically proven nootropic” | Human trials exist only in Russian cerebrovascular medicine, small and single-country; no Western RCTs |
| ”Boosts BDNF” | Supported in rodent studies; human data limited |
| ”FDA-approved in Russia so it’s safe” | Russian approval is not FDA approval; Western safety review is incomplete |
| ”No side effects” | Safety data are limited; the FDA reportedly flagged several concerns for the July 2026 review |
The Bottom Line
Semax has more genuine human clinical history than most grey-market peptides — but that history is Russian, small-scale, and not to Western regulatory standards. Its removal from Category 2 in April 2026 changed its legal footing, not its evidence base. It remains unapproved and not lawfully compoundable pending the July 24, 2026 PCAC review and any rulemaking that follows.
Related: What Is the FDA Peptide Reclassification? | Early July 2026 Roundup